Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | CCR5 | P51681 | 9/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094966 | 0.85 | KDM1A (0.54) | KDM1ACCR5RIPK1RORCMAOA | |
| SCHEMBL1105747 | 0.85 | KDM1A (0.54) | KDM1ACCR5RIPK1RORCMAOA | |
| SCHEMBL1096485 | 0.78 | KDM1A (0.39) | KDM1ACCR5RIPK1RORCTACR1 | |
| SCHEMBL1095901 | 0.78 | KDM1A (0.54) | KDM1ACCR5RIPK1RORCMAOA | |
| SCHEMBL1095794 | 0.77 | CASR (0.45) | KDM1A | |
| SCHEMBL27727620 | 0.77 | CCR5 (0.39) | CCR5 | |
| SCHEMBL4105850 | 0.76 | KDM1A (0.48) | KDM1ACCR5RORC | |
| SCHEMBL4094920 | 0.76 | KDM1A (0.48) | KDM1ACCR5RORC | |
| SCHEMBL4108855 | 0.76 | KDM1A (0.48) | KDM1ACCR5RORC | |
| SCHEMBL1096486 | 0.75 | CCR5 (0.38) | KDM1ACCR5RORCTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | KDM1A 2816/4885CCR5 542/4885RIPK1 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.